Drugs / MKC1106-MT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT00688090 | Jun 2008 → Dec 2009 | melanoma | Mannkind Corporation | Completed | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00033228 | Jan 2002 → Mar 2003 | cutaneous melanoma | Mannkind Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01026051 | Oct 2010 → Sep 2011 | melanoma | Mannkind Corporation | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-30 | Mannkind Corporation | Results Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies mannkindcorp.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-30 | Mannkind Corporation | Studies Show Early Promise of MannKind's Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies mannkindcorp.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MKC1106-MT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00033228 ↗ |
| Modality | Vaccine | “Cancer Vaccine, Immunotherapy” NCT00688090 ↗ |
| Route | Other | “by continuous intranodal infusion” NCT00033228 ↗ |